Secondary Adrenal Insufficiency Following Nivolumab Therapy in a Patient with Metastatic Renal Cell Carcinoma.
- Toshiro Seki,
- Atsushi Yasuda,
- Masayuki Oki,
- Natsumi Kitajima,
- Atsushi Takagi,
- Nobuyuki Nakajima,
- Akira Miyajima,
- Masafumi Fukagawa
Tokai J Exp Clin Med 2017 Sep 20;42(3):115-120. Epub 2017 Sep 20.
Division of Nephrology, Endocrinology and Metabolism, Department of Internal Medicine, Tokai University School of Medicine, 143 Shimokasuya, Iseharashi, Kanagawa 259-1193, Japan.
Currently, nivolumab (an anti-programmed cell death-1 receptor monoclonal antibody) is available for many types of advanced cancers in Japan. However, there have been few detailed case reports about endocrine-related adverse events of this therapy. Here, we report a patient with metastatic renal cell carcinoma who presented with secondary adrenal insufficiency following nivolumab therapy. Read More